½ÃÀ庸°í¼­
»óǰÄÚµå
1461446

¼¼°èÀÇ ¼¼º¸Ç÷ç¶õ(Sevoflurane) ½ÃÀå : ¿ëµµº°, À¯Åëä³Îº°, Áö¿ªº° ½ÃÀå ±Ô¸ð, Á¡À¯À², Àü¸Á, ±âȸ ºÐ¼®(2024-2031³â)

Sevoflurane Market, by Application, by Distribution Channel, and by Region - Size, Share, Outlook, and Opportunity Analysis, 2024 - 2031

¹ßÇàÀÏ: | ¸®¼­Ä¡»ç: Coherent Market Insights | ÆäÀÌÁö Á¤º¸: ¿µ¹® | ¹è¼Û¾È³» : 2-3ÀÏ (¿µ¾÷ÀÏ ±âÁØ)

    
    
    




¡Ø º» »óǰÀº ¿µ¹® ÀÚ·á·Î Çѱ۰ú ¿µ¹® ¸ñÂ÷¿¡ ºÒÀÏÄ¡ÇÏ´Â ³»¿ëÀÌ ÀÖÀ» °æ¿ì ¿µ¹®À» ¿ì¼±ÇÕ´Ï´Ù. Á¤È®ÇÑ °ËÅ並 À§ÇØ ¿µ¹® ¸ñÂ÷¸¦ Âü°íÇØÁֽñ⠹ٶø´Ï´Ù.

¼¼°èÀÇ ¼¼º¸Ç÷ç¶õ ½ÃÀåÀº 2024³â¿¡ 4¾ï 70¸¸ ´Þ·¯·Î ÃßÁ¤µÇ¸ç, ¿¹Ãø ±â°£ Áß(2024-2031³â)¿¡ 4.4%ÀÇ ¿¬Æò±Õ º¹ÇÕ ¼ºÀå·ü(CAGR)À» ³ªÅ¸³¾ °ÍÀ¸·Î ¿¹ÃøµÇ°í ÀÖ½À´Ï´Ù.

º¸°í ´ë»ó ¹üÀ§ º¸°í¼­ ¼¼ºÎÁ¤º¸
±âÁسâ 2023 2023/2024³â ½ÃÀå ±Ô¸ð 4¾ï 70¸¸ ´Þ·¯
½ÇÀû µ¥ÀÌÅÍ 2019-2023³â ¿¹Ãø ±â°£ 2024-2031³â
¿¹Ãø ±â°£ 2023/2024-2030/2031 CAGR: 4.40% 2030/2031³â ¿¹ÃøÄ¡ 5¾ï 4,220¸¸ ´Þ·¯
¼¼º¸Ç÷ç¶õ ¼¼°è ½ÃÀå °¡Ä¡(USD MN), Áö¿ªº°, 2024³â
Sevoflurane Market-IMG1

¼¼º¸Ç÷ç¶õÀº ´ÞÄÞÇÑ Çâ±â¿Í ºÒ¿¬¼ºÀÇ °íºÒ¼ÒÈ­ ¸ÞÆ¿À̼ÒÇÁ·ÎÆÄÀÏ ¿¡Å׸£À̸ç, Àü½Å ¸¶ÃëÀÇ µµÀÔ°ú À¯Áö¸¦ À§ÇÑ ÈíÀÔ ¸¶ÃëÁ¦·Î »ç¿ëµË´Ï´Ù. µ¥½ºÇ÷ç¶õ¿¡ À̾î ÁïÈ¿¼ºÀÌ ÀÖ´Â Èֹ߼º ¸¶ÃëÁ¦ÀÔ´Ï´Ù.

½ÃÀå ¿ªÇÐ

°¢ ½ÃÀåÀº ÈíÀԱ⿡ ÀÇÇÑ ¸¶Ãë Àü´Þ¿¡ µµ¿òÀÌ µÇ´Â ½Å±â¼úÀÇ ÅõÀÔ¿¡ ÁÖ·ÂÇϰí ÀÖÀ¸¸ç, ÀÌ´Â ¿¹Ãø ±â°£ µ¿¾È ¼¼°èÀÇ ¼¼º¸Ç÷ç¶õ ½ÃÀåÀÇ ¼ºÀå¿¡ ±â¿©ÇÒ ¼ö ÀÖ½À´Ï´Ù. ¿¹¸¦ µé¾î, 2022³â 4¿ù ¼¼°è ÀÇ·á ±â¼úÀÇ ¼±µÎ ±â¾÷ÀÎ GE Healthcare´Â Aisys CS2 Anesthesia Delivery SystemÀÇ Àü½Å ¸¶Ãë Àü´ÞÀ» À§ÇÑ ¿£µåŸÀ̵å(Et) Á¦¾î ¼ÒÇÁÆ®¿þ¾î°¡ ¹Ì±¹ ½ÄǰÀǾ౹(FDA))·ÎºÎÅÍ ½ÃÆÇÀü ½ÂÀÎ(PMA)À» ÃëµæÇß´Ù°í ¹ßÇ¥Çß½À´Ï´Ù. ¹Ì±¹¿¡¼­ GE HealthCare´Â Á¾¸» ³óµµ Á¦¾î¸¦ ÅëÇÑ Àü½Å ¸¶Ãë Á¦°øÀ» ½ÂÀÎÇÑ À¯ÀÏÇÑ Á¦Á¶¾÷üÀÔ´Ï´Ù.

¸¶Ãë°¡ ÇÊ¿äÇÑ ¹Ì¿ë ¼ö¼ú Áõ°¡´Â ¼¼°è ¼¼º¸Ç÷ç¶õ ½ÃÀåÀÇ ¼ºÀåÀ» °¡¼ÓÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ¿¹¸¦ µé¾î, 2022³â 4¿ù, ¾ó±¼°ú ¸öÀÇ ¹Ì¿ë ¼ºÇü ¼ö¼ú°ú ¹Ì¿ë ÀÇ·á¿¡¸¸ ƯȭµÈ ¼¼°è À¯¼öÀÇ ÇùȸÀÎ The Aesthetic Society´Â ¸Å³â Ç×·ÊÀÇ Aesthetic Plastic Surgery Statistics(¹Ì¿ë ¼ºÇü ¼ö¼ú Åë°è)¸¦ ¹ßÇ¥Çϰí, ÀÌ ÇùȸÀÇ »õ·Ó°í ´õ Á¤È®ÇÑ µðÁöÅÐ ±â¼úÀ» »ç¿ëÇÏ¿© ¾òÀº µ¥ÀÌÅÍ´Â ¹Ì±¹¿¡¼­ 2021³â¿¡ ¹Ì¿ë ¼ºÇü ¼ö¼úÀÌ Áõ°¡ÇÑ °ÍÀ¸·Î ³ªÅ¸³µ½À´Ï´Ù. ÀÌ µ¥ÀÌÅÍ¿¡ µû¸£¸é ¾ó±¼, °¡½¿, ½Åü ¼ö¼úÀÌ Å©°Ô ´Ã¾î³µ½À´Ï´Ù. º¹ºÎ¼ºÇü¼ú, µÐºÎÁõ´ë¼ú, Áö¹æÈíÀÔ¼úÀº ¸ðµÎ ¹Ì±¹¿¡¼­ 2020³â ÀÌÈÄ ÀαⰡ 63% ±Þ»ó½ÂÇϰí ÀÖ½À´Ï´Ù. dzÈä¼ú, dzÈä/¹ö½ºÆ®¸®ÇÁÆ®, ¹ö½ºÆ®¸®ÇÁÆ®/Ãà¼Ò¼úÀº ¸ðµÎ 48% Áõ°¡Çϰí ÀÖ½À´Ï´Ù.

ÈíÀÔ ¸¶ÃëÁ¦¸¦ Àç»ç¿ëÇÏ´Â ±â¼úÀÇ Ãâ½Ã°¡ Áõ°¡Çϰí ÀÖÀ¸¸ç ¿¹Ãø ±â°£ µ¿¾È ¼ºÀåÀ» °¡¼ÓÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ¿¹¸¦ µé¾î, 2020³â 7¿ù ¹«±Õ¾àÁ¦ÀÇ Á¦Á¶¿Í °ø±ÞÀ¸·Î ¼¼°è¸¦ ¼±µµÇÏ´Â Baxter International Inc.´Â ÀÇ·á±â¼ú±â¾÷ÀÎ ZeoSys Medical°ú ¸¶Ãë°¡½º¸¦ Æ÷ÂøÇÏ¿© ÀçÀÌ¿ëÇÏ´Â ±â¼úÀ» »óǰȭÇÔÀ¸·Î½á Á¤½Ä ÇÕÀÇ Çß´Ù°í ¹ßÇ¥Çß½À´Ï´Ù. Baxter´Â º» °è¾à¿¡ ÀǰÅÇÏ¿© Àü ¼¼°è ÆÇ¸Å±Ç°ú À¯·´ ÀÌ¿ÜÀÇ º» ±â¼úÀÇ »ó¾÷È­¿¡ °üÇÑ µ¶Á¡Àû ¶óÀ̼±½º¸¦ °¡Áö°í ÀÖÀ¸¸ç, ZeoSys Medical»ç¸¦ ÀμöÇÏ´Â µ¶Á¡Àû ¿É¼Ç±ÇÀ» °¡Áö°í ÀÖ½À´Ï´Ù.

º» Á¶»çÀÇ ÁÖ¿ä Æ¯Â¡

  • ÀÌ Á¶»ç º¸°í¼­´Â ¼¼°èÀÇ ¼¼º¸Ç÷ç¶õ ½ÃÀåÀ» »ó¼¼ÇÏ°Ô ºÐ¼®Çϰí, 2023³âÀ» ±âÁسâÀ¸·Î ÇÑ ¿¹Ãø±â°£(2024-2031³â) ½ÃÀå ±Ô¸ð¸¦ Á¦°øÇÕ´Ï´Ù.
  • ¼­·Î ´Ù¸¥ ºÎ¹®¿¡ °ÉÄ£ ÀáÀçÀûÀÎ ¼öÀÍ ±âȸ¸¦ ¹àÇô³»°í ÀÌ ½ÃÀåÀÇ ¸Å·ÂÀûÀÎ ÅõÀÚ Á¦¾È ¸ÅÆ®¸¯½º¸¦ ¼³¸íÇÕ´Ï´Ù.
  • ¶ÇÇÑ ½ÃÀå ¼ºÀå ÃËÁø¿äÀÎ, ÀúÇØ ¿äÀÎ, ±âȸ, ½ÅÁ¦Ç°ÀÇ »ó½Ã ¹× ½ÂÀÎ, Áö¿ªº° Àü¸Á, ÁÖ¿ä ±â¾÷ÀÌ Ã¤¿ëÇÏ´Â °æÀï Àü·« µî¿¡ °üÇÑ Áß¿äÇÑ ÅëÂûÀ» Á¦°øÇÕ´Ï´Ù.
  • ±â¾÷ °³¿ä, À繫 ½ÇÀû, Á¦Ç° Æ÷Æ®Æú¸®¿À, Áö¸®Àû Á¸Àç, À¯Åë Àü·«, ÁÖ¿ä °³¹ß ¹× Àü·«, ¹Ì·¡ °èȹ µîÀÇ ¸Å°³º¯¼ö¸¦ ±â¹ÝÀ¸·Î ¼¼°è ¼¼º¸Ç÷ç¶õ ½ÃÀåÀÇ ÁÖ¿ä ±â¾÷À» ÇÁ·ÎÆÄÀϸµÇÕ´Ï´Ù.
  • ÀÌ º¸°í¼­ÀÇ ÅëÂûÀ» ÅëÇØ ¸¶ÄÉÆÃ ´ã´çÀÚ¿Í ±â¾÷ °æ¿µÁøÀÌ ÇâÈÄ Á¦Ç° Ãâ½Ã, ±â¼ú Çâ»ó, ½ÃÀå È®´ë, ¸¶ÄÉÆÃ Àü¼ú¿¡ ´ëÇÑ Á¤º¸¸¦ ¹ÙÅÁÀ¸·Î ÀÇ»ç °áÁ¤À» ³»¸± ¼ö ÀÖ½À´Ï´Ù.
  • ¼¼º¸Ç÷ç¶õ ¼¼°è ½ÃÀå º¸°í¼­´Â ÅõÀÚÀÚ, °ø±Þ¾÷ü, Á¦Á¶¾÷ü, À¯Åë¾÷ü, ½Å±Ô Âü°¡ÀÚ, À繫 ºÐ¼®°¡ µî ÀÌ ¾÷°èÀÇ ´Ù¾çÇÑ ÀÌÇØ°ü°èÀÚ¸¦ Áö¿øÇÕ´Ï´Ù.
  • ¼¼°èÀÇ ¼¼º¸Ç÷ç¶õ ½ÃÀå ºÐ¼®¿¡ »ç¿ëµÇ´Â ´Ù¾çÇÑ Àü·« ¸ÅÆ®¸¯½º¸¦ ÅëÇØ ÀÌÇØ°ü°èÀÚµéÀº ÀÇ»ç°áÁ¤ÀÌ ¿ëÀÌÇØÁý´Ï´Ù.

¸ñÂ÷

Á¦1Àå Á¶»çÀÇ ¸ñÀû°ú ÀüÁ¦Á¶°Ç

  • Á¶»ç ¸ñÀû
  • ÀüÁ¦Á¶°Ç
  • ¾à¾î

Á¦2Àå ½ÃÀå °³¿ä

  • º¸°í¼­ ¼³¸í
    • ½ÃÀå Á¤ÀÇ¿Í ¹üÀ§
  • ÁÖ¿ä ¿ä¾à
  • Coherent Opportunity Map(COM)

Á¦3Àå ½ÃÀå ¿ªÇÐ, ±ÔÁ¦, µ¿Ç⠺м®

  • ½ÃÀå ¿ªÇÐ
    • ¼ºÀå ÃËÁø¿äÀÎ
    • ¾ïÁ¦¿äÀÎ
    • ½ÃÀå ±âȸ
  • ¿µÇ⠺м®
  • Porter's Five Forces ºÐ¼®
  • ¾÷°è µ¿Çâ
  • ÁÖ¿ä ÇÏÀ̶óÀÌÆ®
  • ¿ªÇÐ
  • ȯ±Þ ½Ã³ª¸®¿À
  • ±ÔÁ¦ ½Ã³ª¸®¿À
  • Á¦Ç° Ãâ½Ã ¹× ½ÂÀÎ
  • Àμö¿Í Çù¾÷ ½Ã³ª¸®¿À

Á¦4Àå ¼¼°èÀÇ ¼¼º¸Ç÷ç¶õ ½ÃÀå - Äڷγª¹ÙÀÌ·¯½º(COVID-19) ÆÒµ¥¹ÍÀÇ ¿µÇâ

  • COVID-19 ¿ªÇÐ
  • COVID-19¿¡ ÀÇÇÑ ¼¼º¸Ç÷ç¶õ ¼ö¿ä ¹× °ø±Þ¿¡ ´ëÇÑ ¿µÇâ
  • COVID-19°¡ ÇコÄÉ¾î ºÐ¾ß Àüü¿¡ ¹ÌÄ¡´Â ¿µÇâ

Á¦5Àå ¼¼°èÀÇ ¼¼º¸Ç÷ç¶õ ½ÃÀå, ¿ëµµº°(2017-2030³â)

  • µµÀÔ
  • À¯Áöº¸¼ö

Á¦6Àå ¼¼°èÀÇ ¼¼º¸Ç÷ç¶õ ½ÃÀå, À¯Åë ä³Îº°(2017-2030³â)

  • º´¿ø ¾à±¹
  • ¼Ò¸Å ¾à±¹
  • ¿Â¶óÀÎ ¾à±¹

Á¦7Àå ¼¼°èÀÇ ¼¼º¸Ç÷ç¶õ ½ÃÀå, Áö¿ªº°(2017-2030³â)

  • ºÏ¹Ì
  • ¹Ì±¹
  • ij³ª´Ù
  • ¶óƾ¾Æ¸Þ¸®Ä«
  • ºê¶óÁú
  • ¸ß½ÃÄÚ
  • ¾Æ¸£ÇîÆ¼³ª
  • ±âŸ ¶óƾ¾Æ¸Þ¸®Ä«
  • À¯·´
  • µ¶ÀÏ
  • ¿µ±¹
  • ÇÁ¶û½º
  • ÀÌÅ»¸®¾Æ
  • ½ºÆäÀÎ
  • ·¯½Ã¾Æ
  • ±âŸ À¯·´
  • ¾Æ½Ã¾ÆÅÂÆò¾ç
  • Áß±¹
  • Àεµ
  • ÀϺ»
  • È£ÁÖ
  • Çѱ¹
  • ASEAN
  • ±âŸ ¾Æ½Ã¾ÆÅÂÆò¾ç
  • Áßµ¿
  • °ÉÇÁ Çù·Â ȸÀÇ
  • À̽º¶ó¿¤
  • ±âŸ Áßµ¿
  • ¾ÆÇÁ¸®Ä«
  • ³²¾ÆÇÁ¸®Ä«
  • Áß¾Ó ¾ÆÇÁ¸®Ä«
  • ºÏ¾ÆÇÁ¸®Ä«

Á¦8Àå °æÀï ±¸µµ

  • ±â¾÷ ÇÁ·ÎÆÄÀÏ
    • Abbott Laboratories
    • Baxter
    • Piramal Pharma Solutions
    • Manus Aktteva Biopharma LLP
    • Maruishi Pharmaceutical Co.,Ltd.
    • Lunan Pharmaceutical Group
    • Abbvie
    • Wellona Pharma
    • Rewine Pharmaceutical
    • Troikaa Pharmaceuticals Limited

Á¦9Àå ºÐ¼®°¡ Ãßõ

  • Wheel of Fortune
  • Analyst View
  • Coherent Opportunity Map

Á¦10Àå ¼½¼Ç

  • Âü°í¹®Çå
  • Á¶»ç ¹æ¹ý
JHS 24.05.20

The global sevoflurane market is estimated to be valued at USD 400.7 Mn in 2024 and is expected to exhibit a CAGR of 4.4% during the forecast period (2024-2031).

Report Coverage Report Details
Base Year: 2023 Market Size in 2023/2024: US$ 400.7 Mn
Historical Data for: 2019 to 2023 Forecast Period: 2024 to 2031
Forecast Period 2023/2024 to 2030/2031 CAGR: 4.40% 2030/2031 Value Projection: US$ 542.2 Mn
Global Sevoflurane Market Value (USD MN), by Region, 2024
Sevoflurane Market - IMG1

Sevoflurane is a sweet-smelling, nonflammable, highly fluorinated methyl isopropyl ether that is used as an inhalational anesthetic for general anesthesia induction and maintenance. It is the fastest-acting volatile anesthetic after desflurane.

Market Dynamics

Market players are focused on launching new technology to help delivery of anesthesia through inhalers, this could contribute to the growth of the global sevoflurane market over the forecast period. For instance, in April 2022, GE Healthcare, a leading global medical technology company, announced that its end-tidal (Et) Control software for general anesthesia delivery on its Aisys CS2 Anesthesia Delivery System has received pre-market approval (PMA) from the U.S. Food and Drug Administration (FDA). In the U.S., GE Healthcare is the only manufacturer approved to provide general anesthesia with end-tidal concentration control.

Increasing number of aesthetic surgeries requiring anesthesia, is expected to drive the growth of global sevoflurane market. For instance, in April 2022, The Aesthetic Society, world's leading association dedicated solely to facial and body aesthetic plastic surgery and cosmetic medicine issued its annual Aesthetic Plastic Surgery Statistics, which revealed that aesthetic plastic surgery increased in 2021 in U.S. owing to data acquired using the Society's new, more accurate digital technology. The data shows a large growth in procedures for the face, breasts, and body. Abdominoplasty, buttock augmentation, and liposuction have all seen a 63% surge in popularity since 2020 in U.S. Breast augmentation, augmentation/breast lift, and breast lift/reduction treatments all increased by 48%.

Increasing launches of technology to recycle inhaled anesthetics is expected to fuel the growth over forecast period. For instance, in July 2020, Baxter International Inc., a global leader in the production and delivery of sterile medications, announced a formal agreement with ZeoSys Medical, a medical technology company, to commercialize technology to capture and recycle anesthetic gases. Baxter will have worldwide distribution rights and an exclusive license to commercialize the technology outside of Europe, as well as an exclusive option to acquire ZeoSys Medical, under the terms of the agreement.

Key features of the study:

  • This report provides an in-depth analysis of global sevoflurane market, provides market size (US$ Million), and compound annual growth rate (CAGR%) for the forecast period (2024-2031), considering 2023 as the base year
  • It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrix for this market.
  • This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, regional outlook, and competitive strategies adopted by the leading players
  • It profiles leading players in the global sevoflurane market based on the following parameters - company overview, financial performance, product portfolio, geographical presence, distribution strategies, key developments and strategies, and future plans
  • Key companies covered as a part of this study include Abbott Laboratories, Baxter, Piramal Pharma Solutions, Manus Aktteva Biopharma LLP, Maruishi Pharmaceutical Co.,Ltd., Lunan Pharmaceutical Group, Abbvie, Wellona Pharma, Rewine Pharmaceutical, and Troikaa Pharmaceuticals Limited
  • Insights from this report would allow marketers and the management authorities of the companies to make informed decision regarding their future product launch, technology up-gradation, market expansion, and marketing tactics
  • The global sevoflurane market report caters to various stakeholders in this industry including investors, suppliers, manufacturers, distributors, new entrants, and financial analysts
  • Stakeholders would have ease in decision making through various strategy matrices used in analyzing the global sevoflurane market.

Detailed Segmentation:

  • Global Sevoflurane Market, By Application:
    • Induction
    • Maintenance
  • Global Sevoflurane Market, By Distribution Channel:
    • Hospital Pharmacies
    • Retail Pharmacies
    • Online Pharmacies
  • Global Sevoflurane Market, By Region:
    • North America
    • Latin America
    • Europe
    • Asia Pacific
    • Middle East
    • Africa
  • Company Profiles
    • Abbott Laboratories
    • Baxter
    • Piramal Pharma Solutions
    • Manus Aktteva Biopharma LLP
    • Maruishi Pharmaceutical Co.,Ltd.
    • Lunan Pharmaceutical Group
    • Abbvie
    • Wellona Pharma
    • Rewine Pharmaceutical
    • Troikaa Pharmaceuticals Limited

Table of Contents

1. Research Objectives and Assumptions

  • Research Objectives
  • Assumptions
  • Abbreviations

2. Market Overview

  • Report Description
    • Market Definition and Scope
  • Executive Summary
    • Market Snippet, By Application
    • Market Snippet, By Distribution Channel
    • Market Snippet, By Region
  • Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

  • Market Dynamics
    • Drivers
    • Restraints
    • Market Opportunities
  • Impact Analysis
  • Porter's Analysis
  • Industry Trends
  • Key Highlights
  • Epidemiology
  • Reimbursement Scenario
  • Regulatory Scenario
  • Product Launch and Approvals
  • Acquisition and Collaboration Scenario

4. Global Sevoflurane Market - Impact of Coronavirus (COVID-19) Pandemic

  • COVID-19 Epidemiology
  • Impact of COVID-19 on demand and supply of sevoflurane
  • Impact of COVID-19 on the overall healthcare sector

5. Global Sevoflurane Market, By Application, 2017-2030 (US$ Million)

  • Introduction
    • Market Share Analysis, 2022 and 2030 (%)
    • Y-o-Y Growth Analysis, 2018-2030
    • Segment Trends
  • Induction
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Million)
  • Maintenance
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Million)

6. Global Sevoflurane Market, By Distribution Channel, 2017-2030 (US$ Million)

  • Introduction
    • Market Share Analysis, 2022 and 2030 (%)
    • Y-o-Y Growth Analysis, 2018-2030
    • Segment Trends
  • Hospital Pharmacies
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Million)
  • Retail Pharmacies
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Million)
  • Online Pharmacies
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Million)

7. Global Sevoflurane Market, By Region, 2017-2030 (US$ Million)

  • Introduction
    • Market Share Analysis, By Region, 2022 and 2030 (%)
    • Y-o-Y Growth Analysis, For Region, 2018-2030
    • Regional Trends
  • North America
    • Market Size and Forecast, By Application, 2017-2030 (US$ Mn)
    • Market Size and Forecast, By Distribution Channel, 2017-2030 (US$ Mn)
  • U.S.
  • Canada
  • Latin America
    • Market Size and Forecast, By Application, 2017-2030 (US$ Mn)
    • Market Size and Forecast, By Distribution Channel, 2017-2030 (US$ Mn)
    • Market Size and Forecast, By Country, 2017-2030 (US$ Mn)
  • Brazil
  • Mexico
  • Argentina
  • Rest of Latin America
  • Europe
    • Market Size and Forecast, By Application, 2017-2030 (US$ Mn)
    • Market Size and Forecast, By Distribution Channel, 2017-2030 (US$ Mn)
    • Market Size and Forecast, By Country, 2017-2030 (US$ Mn)
  • Germany
  • U.K.
  • France
  • Italy
  • Spain
  • Russia
  • Rest of Europe
  • Asia Pacific
    • Market Size and Forecast, By Application, 2017-2030 (US$ Mn)
    • Market Size and Forecast, By Distribution Channel, 2017-2030 (US$ Mn)
    • Market Size and Forecast, By Country, 2017-2030 (US$ Mn)
  • China
  • India
  • Japan
  • Australia
  • South Korea
  • ASEAN
  • Rest of Asia Pacific
  • Middle East
    • Market Size and Forecast, By Application, 2017-2030 (US$ Mn)
    • Market Size and Forecast, By Distribution Channel, 2017-2030 (US$ Mn)
    • Market Size and Forecast, By Country, 2017-2030 (US$ Mn)
  • GCC
  • Israel
  • Rest of Middle East
  • Africa
    • Market Size and Forecast, By Application, 2017-2030 (US$ Mn)
    • Market Size and Forecast, By Distribution Channel, 2017-2030 (US$ Mn)
    • Market Size and Forecast, By Country/Region, 2017-2030 (US$ Mn)
  • South Africa
  • Central Africa
  • North Africa

8. Competitive Landscape

  • Company Profiles
    • Abbott Laboratories*
  • Company Overview
  • Product Portfolio
  • Financial Performance
  • Recent Developments/Updates
  • Strategies
    • Baxter
    • Piramal Pharma Solutions
    • Manus Aktteva Biopharma LLP
    • Maruishi Pharmaceutical Co.,Ltd.
    • Lunan Pharmaceutical Group
    • Abbvie
    • Wellona Pharma
    • Rewine Pharmaceutical
    • Troikaa Pharmaceuticals Limited

9. Analyst Recommendation

  • Wheel of Fortune
  • Analyst View
  • Coherent Opportunity Map

10. Section

  • References
  • Research Methodology
  • About Us and Sales Contact
ºñ±³¸®½ºÆ®
0 °ÇÀÇ »óǰÀ» ¼±Åà Áß
»óǰ ºñ±³Çϱâ
Àüü»èÁ¦